EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

The Effectiveness of Plecanatide for Treating Constipation and Bloating in Patients Aged 18 to 40 Years With Irritable Bowel Syndrome: Utilization of a New Composite Trisymptom Endpoint

Darren M Brenner iD, Andrea S Shin, Adam P Laitman, Jill K Deutsch, David C Kunkel

Journal of Gastroenterology and Hepatology · 2025

DOI: 10.1111/jgh.70119 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Darren M Brenner und 4 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine-Gastroenterology, Northwestern University-Feinberg School of Medicine, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Constipation, Natriuretic Peptides, Flatulence. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Salix Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Irritable bowel syndrome with constipation (IBS‐C) is characterized by multiple sensory symptoms, including abdominal pain, bloating, and bowel habit alterations. Therapeutic response should address all components. This study assesses a new exploratory trisymptom composite efficacy endpoint in an IBS‐C population of young adults with bloating treated with plecanatide.

Methods

Pooled data were analyzed from two phase 3, randomized, double‐blind trials. Patients (18–40 years) with IBS‐C and baseline bloating (score ≥ 1) received plecanatide 3 mg or placebo for 12 weeks. The composite response definition was simultaneous improvement from baseline in three symptoms (abdominal pain, bloating, and complete spontaneous bowel movements [CSBMs]/week) for ≥ 6 of 12 weeks using several thresholds (≥ 2‐point or ≥ 30% or ≥ 40% improvement in abdominal pain and bloating plus an increase of ≥ 1 or ≥ 2 CSBMs in the same week).

Results

Six hundred and five adults were included (plecanatide [ n = 313]; placebo [ n = 292]). Plecanatide/placebo baseline mean symptom scores were 6.2/6.4 for abdominal pain and 6.4/6.6 for bloating; both had a mean of 0.2 CSBMs/week. Significantly more patients in plecanatide versus placebo groups ( p ≤ 0.01 for all comparisons) were trisymptom composite responders by several stringent thresholds, including ≥ 30% improvement in pain and bloating plus ≥ 1 CSBM/week increase (23.3% vs. 13.4%; p = 0.002) and ≥ 30% improvement in pain and bloating plus ≥ 2 CSBMs/week increase (19.5% vs. 8.9%; p < 0.001). Plecanatide was well tolerated.

Conclusion

Plecanatide simultaneously and significantly improved combined symptoms of abdominal pain, bloating, and CSBM frequency at varying thresholds. Plecanatide is effective in improving global IBS‐C symptoms in individuals with bloating. Trial Registration: ClinicalTrials.gov identifiers—NCT02387359 and NCT02493452.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Irritable Bowel SyndromeConstipationNatriuretic PeptidesFlatulenceHumansAdultMaleFemaleAdolescentYoung AdultDouble-Blind MethodTreatment OutcomeAbdominal PainDefecation

Stichwörter der Autor:innen

abdominal painbloatingconstipationguanylate cyclase C agonistsirritable bowel syndrome

Substanzen

plecanatideNatriuretic Peptides

Autor:innen und Institutionen

  • Internal Medicine-Gastroenterology, Northwestern University-Feinberg School of Medicine, Chicago, Illinois, USA.
  • Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
  • Salix Pharmaceuticals, Bridgewater, New Jersey, USA.
  • Section of Digestive Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
  • Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.

ORCID-Profile: Darren M Brenner

Förderung

  • Salix Pharmaceuticals

Zitieren

APA

Brenner, D. M., Shin, A. S., Laitman, A. P., Deutsch, J. K., & Kunkel, D. C. (2025). The Effectiveness of Plecanatide for Treating Constipation and Bloating in Patients Aged 18 to 40 Years With Irritable Bowel Syndrome: Utilization of a New Composite Trisymptom Endpoint. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70119

Vancouver

Brenner DM, Shin AS, Laitman AP, Deutsch JK, Kunkel DC. The Effectiveness of Plecanatide for Treating Constipation and Bloating in Patients Aged 18 to 40 Years With Irritable Bowel Syndrome: Utilization of a New Composite Trisymptom Endpoint. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.70119

BibTeX
@article{Brenner2025,
  author = {Brenner, Darren M and Shin, Andrea S and Laitman, Adam P and Deutsch, Jill K and Kunkel, David C},
  title = {The Effectiveness of Plecanatide for Treating Constipation and Bloating in Patients Aged 18 to 40 Years With Irritable Bowel Syndrome: Utilization of a New Composite Trisymptom Endpoint},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1111/jgh.70119}
}
Kostenlos starten →